Patients with previously treated tuberculosis no longer neglected

Clinical Infectious Diseases

Volumn 44, Issue 1, 2007, Pages 61-64

  Zignol, Matteo ^a   Wright, Abigail ^a   Jaramillo, Ernesto ^a   Nunn, Paul ^a   Raviglione, Mario C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ANAMNESIS; DISEASE TRANSMISSION; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SEX; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; TREATMENT FAILURE; TUBERCULOSIS; WORLD HEALTH;

EID: 33845697718     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/509328     Document Type: Review

References (19)

1. World Health Organization (WHO). Global tuberculosis control. WHO report 2006. WHO/HTM/TB/2006.361. Geneva: WHO, 2006.
2. Raviglione MG, Uplekar M. WHO's new STOP TB Strategy. Lancet 2006; 367:952-5.
3. United Nations Statistics Division. Millennium indicators database. New York, NY: United Nations Statistics Division, 2004. Available at: http://unstats.un.org/unsd/default.htm. Accessed 12 November 2006.
4. Tuberculosis Coalition for Technical Assistance. International standards for tuberculosis care. Available at: http://www.who.int/tb/publications/2006/ istc_report.pdf. Accessed 12 November 2006.
5. STOP TB Partnership, World Health Organization (WHO). Global plan to stop TB 2006-2015. WHO/HTM/STB/2006.35. Geneva: WHO, 2006.
6. World Health Organization (WHO). Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/TB/2003.313. Geneva: WHO, 2003.
7. Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3:282-7.
8. Chiang CY, Riley LW. Exogenous reinfection in tuberculosis. Lancet Infect Dis 2005; 5: 629-36.
9. World Health Organization (WHO). Anti-tuberculosis drug resistance in the world: report 3. WHO/HTM/TB/2004.343. Geneva: WHO, 2004.
10. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
11. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5:887-93.
12. Gninafon M, Tawo L, Kassa F, et al. Outcome of tuberculosis retreatment in routine conditions in Cotonou, Benin. Int J Tuberc Lung Dis 2004; 8:1242-7.
13. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537-45.
14. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37:101-12.
15. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356:1470-4.
16. Centers for Disease Control and Prevention. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991; 40: 585-91.
17. Uplekar M, Juvekar S, Morankar S, Rangan S, Nunn P. Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis 1998; 2:324-9.
18. Floyd K, Arora VK, Murthy KJ, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ 2006; 84:437-45.
19. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: WHO, 2006.